695 related articles for article (PubMed ID: 11110233)
1. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Guenther LC; Poulin YP; Pariser DM
Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
[TBL] [Abstract][Full Text] [Related]
2. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis.
Green L; Sadoff W
J Cutan Med Surg; 2002; 6(2):95-102. PubMed ID: 11992180
[TBL] [Abstract][Full Text] [Related]
3. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
Poulin YP
Cutis; 1999 Jan; 63(1):41-8. PubMed ID: 9951595
[TBL] [Abstract][Full Text] [Related]
4. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
Bowman PH; Maloney JE; Koo JY
J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489
[TBL] [Abstract][Full Text] [Related]
5. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis.
Koo JY; Martin D
Int J Dermatol; 2001 Mar; 40(3):210-2. PubMed ID: 11422529
[No Abstract] [Full Text] [Related]
6. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
Lebwohl M; Ast E; Callen JP; Cullen SI; Hong SR; Kulp-Shorten CL; Lowe NJ; Phillips TJ; Rosen T; Wolf DI; Quell JM; Sefton J; Lue JC; Gibson JR; Chandraratna RA
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):705-11. PubMed ID: 9591815
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis.
Kaur I; Dogra S; Jain R; Kumar B
Indian J Dermatol Venereol Leprol; 2008; 74(5):471-4. PubMed ID: 19052406
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.
Coynik D
Cutis; 2000 Dec; 66(6 Suppl):19-24. PubMed ID: 11147087
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
10. An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.
Tanghetti EA;
Cutis; 2000 Dec; 66(6 Suppl):12-8. PubMed ID: 11147086
[TBL] [Abstract][Full Text] [Related]
11. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
Koo J; Cuffie CA; Tanner DJ; Bressinck R; Cornell RC; DeVillez RL; Edwards L; Breneman DL; Piacquadio DJ; Guzzo CA; Monroe EW
Clin Ther; 1998; 20(2):283-91. PubMed ID: 9589819
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
Tzung TY; Wu JC; Hsu NJ; Chen YH; Ger LP
Acta Derm Venereol; 2005; 85(3):236-9. PubMed ID: 16040409
[TBL] [Abstract][Full Text] [Related]
13. Instrumental evaluation of retinoid-induced skin irritation.
Stücker M; Hoffmann M; Altmeyer P
Skin Res Technol; 2002 May; 8(2):133-40. PubMed ID: 12060479
[TBL] [Abstract][Full Text] [Related]
14. Optimizing treatment with topical tazarotene.
Guenther LC
Am J Clin Dermatol; 2003; 4(3):197-202. PubMed ID: 12627995
[TBL] [Abstract][Full Text] [Related]
15. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.
Krueger GG; Drake LA; Elias PM; Lowe NJ; Guzzo C; Weinstein GD; Lew-Kaya DA; Lue JC; Sefton J; Chandraratna RA
Arch Dermatol; 1998 Jan; 134(1):57-60. PubMed ID: 9449910
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study.
Angelo JS; Kar BR; Thomas J
Indian J Dermatol Venereol Leprol; 2007; 73(1):65. PubMed ID: 17319037
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
20. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.
Lebwohl MG; Breneman DL; Goffe BS; Grossman JR; Ling MR; Milbauer J; Pincus SH; Sibbald RG; Swinyer LJ; Weinstein GD; Lew-Kaya DA; Lue JC; Gibson JR; Sefton J
J Am Acad Dermatol; 1998 Oct; 39(4 Pt 1):590-6. PubMed ID: 9777766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
